

Freedom of Information request 436-23

Request

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following three questions:

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
 - Adalimumab – Humira
 - Adalimumab Biosimilar
 - Filgotinib
 - Golimumab
 - Infliximab – Remicade
 - Infliximab Biosimilar
 - Ozanimod
 - Tofacitinib
 - Upadacitinib
 - Ustekinumab
 - Vedolizumab
 - Vedolizumab Injections ONLY (pre-filled pens or syringes)

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
 - Adalimumab – Humira
 - Adalimumab Biosimilar
 - Filgotinib
 - Golimumab
 - Infliximab – Remicade
 - Infliximab Biosimilar
 - Ozanimod
 - Tofacitinib
 - Upadacitinib
 - Ustekinumab
 - Vedolizumab
 - Vedolizumab Injections ONLY (pre-filled pens or syringes)

3. Does your trust participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.

Response

1. The number of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs is:

Adalimumab – Humira	0
Adalimumab Biosimilar	19
Filgotinib	0
Golimumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	12
Ozanimod	0
Tofacitinib	0
Upadacitinib	0
Ustekinumab	6
Vedolizumab	6
Vedolizumab Injections ONLY (pre-filled pens or syringes)	0

2. The number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs is:

Adalimumab – Humira	0
Adalimumab Biosimilar	7
Filgotinib	0
Golimumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	7
Ozanimod	0
Tofacitinib	0
Upadacitinib	0
Ustekinumab	0
Vedolizumab	5
Vedolizumab Injections ONLY (pre-filled pens or syringes)	0

3. There are currently no Ulcerative Colitis treatment trials open at NHS Borders.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **436-23** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.